HI
GANX icon

Hoey Investments’s Gain Therapeutics GANX Stock Holding History

Hoey Investments’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500
Closed -$1.56K – 355
2022
Q4 		$1.56K Hold
500
– – ﹤0.01% 268
2022
Q3 		$2K Hold
500
– – ﹤0.01% 285
2022
Q2 		$2K Buy
+500
New +$1.73K ﹤0.01% 255

Other funds holding GANX

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Hoey Investments's GANX Position: Q1 2023 in Review

Hoey Investments sold out of Gain Therapeutics (GANX) in Q1 2023, closing a stake of 500 shares — an estimated $1.56K sold.

Hoey Investments first reported a position in GANX in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 22 funds tracked by Wall St. Rank hold GANX as of Q1 2023.

  • Hoey Investments reported no remaining Gain Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Hoey Investments sold 500 Gain Therapeutics shares in Q1 2023, an estimated $1.56K.
  • Hoey Investments first reported a position in Gain Therapeutics in Q2 2022 and held it in 3 quarters.
  • Hoey Investments's Gain Therapeutics position peaked at $2K in Q3 2022.
  • 22 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2023.

Based on Hoey Investments's 13F filing for Q1 2023, filed 11 May 2023.